



# What's New

**Stijn Rogiers (on behalf of CDISC, Peter Van Reusel – Chief Standards Officer)**

*Principal Industry Consultant, Global Health and Life Sciences Practice, SAS*

*CDISC E3C member*



# 2018 Goals



1

**Build a customer-centric Culture.**



2

**Generate greater member value.**



3

**Ensure sustainability of CDISC Standards.**



4

**Optimize standards development and release process.**



5

**Lay the foundation for a CDISC 2.0 Vision.**




# Agenda

## 1. Rebranding

## 2. Blue Ribbon Commission


## 3. Overview of TA work

## 4. Proof of Concept



cdisc

# Brand Essence



# Brand Personality

## Passionate

**Inspired** but not over-zealous  
**Resolute** but not inflexible  
**Purpose-driven** but not impractical

## Inclusive

**Open** but not without a perspective  
**Collaborative** but not passive  
**Partners** but not pushovers

## Expert

**Confident** but not arrogant  
**Authoritative** but not dictatorial  
**Astute** but not pretentious

## Enterprising

**Visionary** but not idealistic  
**Intrepid** but not reckless  
**Influential** but not domineering

# CDISC brand platform

## Brand essence


The compelling core idea of your brand

## Brand personality

Traits evident in all you say and do

## Brand pillars

Key strengths that form the foundation of your promise





# Agenda

1. Rebranding


**2. Blue Ribbon Commission**

3. Overview of TA work

4. Proof of Concept



# Timeline for Blue Ribbon Commission



# Commissioners



## Co-Chairs

- Joyce Sensmeier, RN (HIMSS)
- Dr. Rob Califf (Verily, Duke University, former FDA)

## Academia

- Dr. Barbara Bierer (Harvard, MRCT, Vivly)
- Dr. Laura Merson (Oxford University, IDDO)
- Dr. Frank Rockhold (Duke University)
- John Speakman (NYU Langone)
- Dr. Sam Volchenbom  
(University of Chicago, Litmus Health)
- Dr. Anita Walden  
(University Arkansas for Medical Sciences)

## Regulators

- Dr. Yuki Ando (PMDA)
- Dr. Allison Cave (EMA)
- Dr. Lilliam Rosario (US FDA)
- Helena Sviglin (US FDA)

## Biotech, Devices

- Paul Franson (Medtronic, Inc.)
- Joanna Koft (Biogen)

## Nonprofit Partners

- Scott Bahlavooni (PhUSE)
- Dr. Lynn Hudson (C-Path)
- Maria Picone (TREND Community)

## Pharmaceuticals

- Jonathan Chainey (Roche, CAC)
- Dr. Hidetoshi Misawa (Pfizer, CDISC J3C)
- Dr. Ulo Palm (Allergan) and Manny Anid (Allergan)
- Dr. Zibao Zhang (dMed, CDISC C3C)

# Commissioners



## Government Agencies

- Dr. Ken Gersing (NIH/NCATS)
- Dr. Tatsuya Maruyama (AMED)
- Dr. Lyuba Remenik (NIH/NCI)

## Technology/Services

- Dr. Wenjun Bao (SAS JMP)
- Dr. Jeff Brown (Sentinel, Harvard Pilgrim)
- Dave Evans (Accenture)
- Hugh Glover (Blue Wave Informatics)
- Dr. C. David Hardison (Deloitte)
- Dave Ibersen-Hurst (Assero Limited)

## CROs/Labs

- Sherry Chou (Parexel)
- Phil Pochon (Covance)

## Research Funders

- Scott Kahn (Helmsley Charitable Trust)
- Dr. Steven Kern (Gates Foundation)
- Dr. Jennifer O'Callaghan (Wellcome Trust)

## Staff

- David R. Bobbitt, MSc, MBA
- Anthony Chow
- Dr. Sam Hume
- Rhonda Facile, MS
- Marine Laurent
- Bess LeRoy, MPH
- Peter Van Reusel



# Key Insights: #1 Refine the model

- **Focus on the CDISC core business, building excellent standards from inception**
  - Alignment across the standards for ETE automation
  - A machine-readable protocol standard
  - Move to a 3D model back-end built on biomedical concepts
  - A refined model is the best way to respond to new technologies, new sources of data
- **Support consistent implementation**
  - Continue and expand educational offerings
  - Metadata to transform data across the foundational standards
  - Completeness of new versions of the standards
  - A majority of Commissioners wants CDISC to consider offering implementation advice

# Key Insights: #2 Volunteers and #3 Focus & Clarity

- **Optimize the volunteer laborforce**

- Ask member companies for volunteers on specific projects but not as a condition of membership
- Train volunteers to utilize CDISC SHARE for standards development
- Centralize strategy for teams
- Utilize technology tools to help volunteers focus on the core strengths
- Utilize staff to reduce bottlenecks in development

- **Focus and clarity**

- Be excessively transparent
- Reduce high threshold to entry



# Key Insight: #4 Build a strong standards ecosystem

- More access to CDISC SHARE API
- Be very specific, strategic in mappings to other terminologies and standards in SHARE, but resist the urges for total interoperability Support developers, open source to build tools on SHARE API
- Launch CDISC certification program
- Observe and be engaged with: HL7 FHIR, AI/machine learning, IOT, medical devices and wearables, BYOD data



## Key Insight: #5 Rely on key partnerships

- **CDISC should be a good partner, fair and transparent**
- **Some areas where other partners should lead**
  - Curation of donated data
  - Data sharing platforms
  - Development of a machine-readable protocol standard
  - Voice of the patient/ways to share data back with patients



# Key Insight: #6 Growth

- **Growth by use case: support expanded use of CDISC standards by academics**
  - Specific trainings, tools
  - Partner with funders, open science advocates, data sharing platforms
- **Geographic Growth**
  - China, India, EU, UK post-Brexit
  - Other global markets: South Korea, Australia, New Zealand, Singapore
  - Be opportunistic!





# Key Insight: #7 Membership and revenue

- Consider a “freemium” model for CDISC SHARE
- Approach funders of academic research and data sharing to support the academic use case development
- Earn revenue from a certification program
- Consider tweaking the membership model for academics
- Listen to members: what do they need and expect?



# Areas where consensus has eluded us...

- RWD
- Branding of the foundational standards
- CDISC offers implementation advice/services
- Simplified versioning system
- Deprecation system



# Agenda

1. Rebranding
2. Blue Ribbon Commission
- 3. Overview of TA work**
4. Proof of Concept



- Select Therapeutic Area -

## Therapeutic Areas

Therapeutic Area (TA) Standards extend the Foundational Standards to represent data that pertains to specific disease areas. TA Standards include disease-specific metadata, examples and guidance on implementing CDISC standards for a variety of uses, including global regulatory submissions.

### Published User Guides

Therapeutic Area	Guides Contain:
Alzheimer's	Terminology, SDTM
Asthma	Terminology, SDTM
Breast Cancer	Terminology, CDASH, SDTM, ADaM
Cardiovascular	Terminology, SDTM

### CURRENT PUBLIC REVIEWS

Confirmed Data Endpoints for Exchange (CoDEx) for SENDIG v3.1 Data  
Comments Due by: 30 Oct 2018

Traditional Chinese Medicine for Coronary Artery Disease - Angina v1.0  
Comments Due by: 30 Oct 2018

CGI and PGI Questionnaires Supplements to the SDTMIG  
Comments Due by: 30 Oct 2018


ADaM Conformance Rules v2.0  
Comments Due by: 12 Nov 2018

Nutrition Therapeutic Area User Guide v1.0  
Comments Due by: 10 Dec 2018

Lung Cancer Therapeutic Area User Guide v1.0  
Comments Due by: 21 Dec 2018

<https://www.cdisc.org/standards/therapeutic-areas>

# CDISC Standards



\*The full list of foundational standards is available at <https://www.cdisc.org/standards/foundational>



# Therapeutic Area User Guides (TAUGs)

- Guides for the implementation of CDISC foundational standards in specific disease areas
- Include examples from *across CDISC foundational standards*
- TAUGs extend the foundational standards and thus they must be used in conjunction with the foundational standards
- Based on biomedical concepts identified by subject matter experts

# Overview of Therapeutic Area Work

## Upcoming Publications

- Colorectal Cancer v1.0
- HIV Prevention and Treatment v1.0
- Post Traumatic Stress Disorder v1.0
- Traditional Chinese Medicine for CAD v1.0
- CV Imaging v1.0

## Current Public Reviews

- Nutrition v1.0 –  
*Comments Due 10 Dec 2018*
- Lung Cancer v1.0 –  
*Comments Due 21 Dec 2018*

# Overview of Therapeutic Area Work

- **Upcoming Public Reviews**

- CDAD – 2<sup>nd</sup> Public Review (30 days) for additional FMT example
- Animal Rule (Nonclinical)

- **Ongoing Work**

- Type 1 Diabetes (Pediatrics and Devices)
- Traditional Chinese Medicine – Acupuncture

- **Newly Forming Therapeutic Areas – Seeking Volunteers**

- Type 1 Diabetes (Prevention and Exercise)
- Crohn's Disease
- Acute Kidney Injury
- Congestive Heart Failure
- Psoriasis





# Agenda

1. Rebranding
2. Blue Ribbon Commission
3. Overview of TA work
4. **Proof of Concept**

# Defined Structures

- CDISC Foundational models provide much needed structure

- Normative Content
- 2 dimensional (tables, columns)
- Standard to represent data

- The information itself is not defined

- We do not need new structures
- We need to define
  - Entities
  - Semantics (meaning)
  - Relationships between information
  - Rules in the data lifecycle

Question Text	Prompt	SDTM or CDASH Variable Name	BRIDG	Definition	CRF Completion Instructions	Information for Sponsors	Core
1 Were vital signs collected?	Vital signs collected?	VSPERF	PerformedObservation Result value	General prompt question regarding whether or not any VS were collected during the study. This provides verification that all other fields on the CRF were deliberately left blank.  (NY) (See Section 2.2)	Indicate if the vital signs were collected. If yes, include the appropriate details where indicated on the CRF.	The intent purpose of collecting this field is to help with data cleaning and monitoring. See Best Practice Section 3.4, FAQ #6.  For the SDTM-based dataset, SDTMIG variable VSSTAT is derived from a "No" value in VSPERF. This field does not map directly to an SDTM variable.	O
2 On what date were the measurements performed?	Date	VSDAT	PerformedActivity dateRange*	Date of measurements.	Record date of measurements using this format (DD-MON-YYYY).	The date of measurement can be derived from a collected date of visit and in such cases a separate measurement date field is not required.  For the SDTM-based dataset, the SDTM IG variable VSSTRT is derived from the date of measurement.	R/C

vs.xpt, Vital Signs — Findings, Version 3.2. One record per vital sign measurement per time point per visit per subject, Tabulation

Variable Name	Variable Label	Type	Controlled Terms, Codelist or Format	Role	CDISC Notes	Core
STUDYID	Study Identifier	Char		Identifier	Unique identifier for a study.	Req
DOMAIN	Domain Abbreviation	Char	VS	Identifier	Two-character abbreviation for the domain.	Req
USUBJID	Unique Subject Identifier	Char		Identifier	Identifier used to uniquely identify a subject across all studies for all applications or submissions involving the product.	Req
VSSEQ	Sequence Number	Num		Identifier	Sequence Number given to ensure uniqueness of subject records within a domain. May be any valid number.	Req
VSGRPID	Group ID	Char		Identifier	Used to tie together a block of related records in a single domain for a subject.	Perm
VSSPID	Sponsor-Defined Identifier	Char		Identifier	Sponsor-defined reference number. Perhaps pre-printed on the CRF as an explicit line identifier or defined in the sponsor's operational database.	Perm
VSTESTCD	Vital Signs Test Short Name	Char	(VSTESTCD)	Topic	Short name of the measurement, test, or examination described in VSTEST. It can be used as a column name when converting a dataset from a vertical to a horizontal format. The value in VSTESTCD cannot be longer than 8 characters.	Req

Variable Name	Variable Label	Type	Codelist/ Controlled Terms	Core	CDISC Notes
STUDYID	Study Identifier	Char		Req	DM.STUDYID
USUBJID	Unique Subject Identifier	Char		Req	DM.USUBJID
SUBJID	Subject Identifier for the Study	Char		Req	DM.SUBJID. SUBJID is required in ADSL, but permissible in other datasets.
SITEID	Study Site Identifier	Char		Req	DM.SITEID. SITEID is required in ADSL, but permissible in other datasets.
SITEGRy	Pooled Site Group y	Char		Perm	Character description of a grouping or pooling of clinical sites for analysis purposes. For example, SITEGR3 is the name of a variable containing site group (pooled site) names, where the grouping has been done according to the third site grouping algorithm, defined in variable meta_data. SITEGR3 does not mean the third group of sites.
SITEGRyN	Pooled Site Group y (N)	Num		Perm	The numeric code for SITEGRy. One-to-one mapping to SITEGRy within a study.
REGIONy	Geographic Region y	Char		Perm	Character description of geographical region. For example, REGION1 might have values of 'Asia', 'Europe', 'North America', 'Rest of World'; REGION2 might have values of 'United States', 'Rest of World'.
REGIONyN	Geographic Region y (N)	Num		Perm	The numeric code for REGIONy. Orders REGIONy for analysis and reporting. One-to-one mapping to REGIONy within a study.



# Why Change ?


- Industry needs are evolving
- Our standards need to enable end-to-end automation
- Our standards need to be machine-readable
- Continuous need to be more efficient and save costs
- We want non-standard experts to use our standards

# What is the CDISC proof of concept?

- A serious attempt to store and use data standards as linked metadata
- Create and store standards as concepts and create meaning between concepts
- Add computer readable metadata which enables end to end functionality
- The Proof of Concept will test and demonstrate this functionality
- Evolve from normative to informative standards
- Make implicit relationships explicit

# Store Standards in Concept Maps 1/2


- Example of **biomedical concept**



- Data is expressed through the CDISC Foundational Models
- Can map to BRIDG Reference Model


# Store Standards in Concept Maps 2/2

- Example of **statistical concept**






# Use Case 1: End to Start specification






# Use Case 2: Start to End Metadata



# Use Case 3: Start to End Data Processing





# Proof Of Concept Outline

- The Proof of Concept will need an estimated 18 months
- We need help from our community
  - Define Use Cases
  - Provide Examples of success, experience
  - Provide demo data
- Agile Development, regular presentations in user groups



# Expected POC Outcome

- **POC Outcome**
  - What works and what doesn't
- **Can we create true end to end**
  - Technology Gap Analysis
  - Standards Gap Analysis
- **Building a base for the future**
  - Scale up to deliver the standards metadata needed
  - Effort calculation
  - Cost / Benefit Analysis
  - Partnerships with vendors to ensure tools are made available

# Questions





# THANK YOU !

**Stijn Rogiers (on behalf of CDISC, Peter Van Reusel – Chief Standards Officer)**

*Principal Industry Consultant, Global Health and Life Sciences Practice, SAS*

*CDISC E3C member*

